Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib….The ABL1, ABL2, and CSF1R fusions were sensitive to the ABL-class inhibitors imatinib (50% inhibitory concentration [IC50], 135 to 900 nM) (data not shown) and dasatinib (IC50, 1 to 2 nM), whereas PAX5–JAK2 was not sensitive to these agents (Fig. 3B).